Acrodermatitis chronica atrophicans overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 7: Line 7:


==Historical Perspective==
==Historical Perspective==
The first record of ACA was made in 1883 in Breslau, Germany, where a physician named Alfred Buchwald first delineated it. [[Herxheimer reaction|Herxheimer]] and Hartmann described it in 1902 as a "tissue paper" like [[cutaneous]] atrophy.
First record of [[acrodermatitis chronica atrophicans]] was made in 1883 in Breslau, Germany, where a [[physician]] named Alfred Buchwald first delineated it. Later in 1902 Herxheimer and Hartmann described it as a "tissue paper" like [[cutaneous]] [[atrophy]] and there were first [[physicians]] that came up with [[acrodermatitis chronica atrophicans]]'s name. They described the biphasic manner of this [[disease]] by demonstrating both [[inflammation|inflammatory]] and [[atrophy|atrophic phases]] of it. In 1950s the possibility of [[human]] to [[human]] [[Transmission (medicine)|transmission]] was discussed.For the first time in 1984, [[borrelia]] was discovered as the responsible [[etiology]] of [[acrodermatitis chronica atrophicans]].


==Treatment==
==Treatment==

Revision as of 15:55, 13 June 2021

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Acrodermatitis chronica atrophicans Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Acrodermatitis chronica atrophicans from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acrodermatitis chronica atrophicans overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acrodermatitis chronica atrophicans overview

CDC on Acrodermatitis chronica atrophicans overview

Acrodermatitis chronica atrophicans overview in the news

Blogs on Acrodermatitis chronica atrophicans overview

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Acrodermatitis chronica atrophicans overview

Overview

Acrodermatitis chronica atrophicans is a skin rash indicative of the third or late stage of European Lyme borreliosis. It is a dermatological condition that takes a chronically progressive course and finally leads to a widespread atrophy of the skin. Involvement of the peripheral nervous system is often observed, specifically polyneuropathy.

Historical Perspective

First record of acrodermatitis chronica atrophicans was made in 1883 in Breslau, Germany, where a physician named Alfred Buchwald first delineated it. Later in 1902 Herxheimer and Hartmann described it as a "tissue paper" like cutaneous atrophy and there were first physicians that came up with acrodermatitis chronica atrophicans's name. They described the biphasic manner of this disease by demonstrating both inflammatory and atrophic phases of it. In 1950s the possibility of human to human transmission was discussed.For the first time in 1984, borrelia was discovered as the responsible etiology of acrodermatitis chronica atrophicans.

Treatment

Medical Therapy

Treatment of ACA consists of antibiotics including doxycycline and penicillin for up to four weeks in the acute case.

References

Template:WH Template:WS